Earnings summaries and quarterly performance for LEMAITRE VASCULAR.
Executive leadership at LEMAITRE VASCULAR.
Board of directors at LEMAITRE VASCULAR.
Research analysts who have asked questions during LEMAITRE VASCULAR earnings calls.
Brett Fishbin
KeyBanc Capital Markets
6 questions for LMAT
Also covers: ALC, COO, ICUI +7 more
MP
Michael Petusky
Barrington Research
6 questions for LMAT
Also covers: ANIK, HAE, HSIC +9 more
Daniel Stauder
Citizen JMP
4 questions for LMAT
Also covers: AORT, ATRC, AVNS +2 more
Frank Takkinen
Lake Street Capital Markets
4 questions for LMAT
Also covers: ANGO, AORT, AXGN +18 more
James Sidoti
Sidoti & Company
4 questions for LMAT
Also covers: ANIK, ASRT, GAIA +10 more
MS
Michael Sarcone
Jefferies
4 questions for LMAT
Also covers: ALC, ALGN, AXGN +12 more
RO
Ross Osborn
Cantor Fitzgerald
4 questions for LMAT
Also covers: AXGN, CERS, CVRX +12 more
SK
Suraj Kalia
Oppenheimer & Co. Inc.
4 questions for LMAT
Also covers: ABT, AORT, ATRC +14 more
RW
Rick Wise
Stifel Financial Corp
3 questions for LMAT
Also covers: BDX, BSX, GEHC +9 more
DS
Danny Stauder
Citizens JMP
2 questions for LMAT
Also covers: ATRC, AVNS
FW
Frederick Wise
Stifel
2 questions for LMAT
Also covers: AORT, ATRC, AVNS +13 more
JW
Jason Wittes
Roth Capital Partners, LLC
2 questions for LMAT
Also covers: ALUR, ARAY, ATEC +13 more
KB
Kyle Bauser
B. Riley Securities
2 questions for LMAT
Also covers: ELMD, INFU, IRMD +7 more
NT
Nathan Treybeck
Wells Fargo Securities
2 questions for LMAT
Also covers: IRTC, ITGR, NVRO +2 more
JL
Jacob Lanyak
Oppenheimer
1 question for LMAT
Jim Sidoti
Sidoti & Company, LLC
1 question for LMAT
Also covers: ANIK, GAIA, GOCO +6 more
Shaymus Contorno
Oppenheimer & Co. Inc.
1 question for LMAT
Also covers: TLSI, TNDM, VREX
Recent press releases and 8-K filings for LMAT.
LeMaitre Vascular Reports 2025 Financial Results and Provides 2026 Guidance
LMAT
Earnings
Guidance Update
M&A
- LeMaitre Vascular reported $249,602 thousand in net sales for 2025, and provided 2026 full-year guidance including $280,243 thousand in net sales, a 72.0% gross margin, $77,759 thousand in income from operations, and $2.91 in diluted EPS.
- As of December 31, 2025, LeMaitre Vascular held $290 million in Cash & Investments and has increased its dividend for 15 consecutive years , with the Q1 2026 dividend rising 25% to $0.25 per share.
- The company's growth is driven by a global sales force of 160 representatives as of December 31, 2025 , and 25 acquisitions completed in the last 28 years. LeMaitre Vascular holds a #1 or #2 share in 9 of 12 markets and its product mix included 53% Biologic Implants in 2025.
2 days ago
LeMaitre Vascular Reports Strong Q4 and Full-Year 2025 Results, Issues Positive 2026 Guidance
LMAT
Earnings
Guidance Update
Share Buyback
- LeMaitre Vascular reported strong financial performance for Q4 2025, with 16% sales growth, a 71.7% gross margin, 47% operating income growth, and $0.68 fully diluted earnings per share. For the full year 2025, the company achieved 14% organic revenue growth, a 70.4% adjusted gross margin, 26% adjusted operating margin, and 23% adjusted EPS growth.
- The company provided full-year 2026 guidance, anticipating $280 million in revenue, 12% organic sales growth, a 72.1% gross margin, $77.8 million in operating income (up 21% adjusted), and $2.91 adjusted EPS (up 22% adjusted).
- LeMaitre Vascular's Board of Directors approved a new $100 million share repurchase program and a Q1 2026 dividend of $0.25 per share, representing a 25% year-over-year increase and the 15th consecutive year of dividend increases.
- Key growth drivers in Q4 2025 included grafts up 27%, valvetomes up 20%, and shunts up 18%, with strong regional growth in EMEA (29%) and APAC (20%). International Autograft sales were $4 million in full year 2025 and are expected to reach $10 million in 2026.
- The company plans to expand its direct sales model by going direct in Poland in Q4 2026, which will be its 32nd country.
3 days ago
LeMaitre Vascular Reports Strong Q4 and Full-Year 2025 Results, Provides 2026 Guidance
LMAT
Earnings
Guidance Update
Share Buyback
- LeMaitre Vascular reported strong Q4 2025 results, including 16% sales growth, a 71.7% gross margin, and $0.68 fully diluted earnings per share. For the full year 2025, the company achieved 14% organic revenue growth and 23% adjusted EPS growth.
- The company provided 2026 guidance, projecting $280 million in revenue, 12% organic sales growth, a 72.1% gross margin, and $2.91 earnings per share.
- Strategic highlights include the continued international launch of Artegraft, which generated $4 million in international sales in 2025 and is expected to reach $10 million in 2026, and plans to increase its sales force to 170-180 reps by year-end 2026.
- The board approved a new $100 million share repurchase program and increased the Q1 2026 dividend by 25% to $0.25 per share.
3 days ago
LeMaitre Vascular Reports Strong Q4 and Full Year 2025 Results, Issues 2026 Guidance
LMAT
Earnings
Guidance Update
Share Buyback
- LeMaitre Vascular reported strong Q4 2025 sales growth of 16% and 47% operating income growth, achieving a 71.7% gross margin and $0.68 diluted EPS. For the full year 2025, organic revenue grew 14%, and adjusted EPS increased 23%.
- The company provided 2026 guidance anticipating $280 million in revenue, 12% organic sales growth, and $2.91 adjusted EPS. Strategic plans include a blended 8% price increase for 2026, growing the sales force to 170-180 reps, and expanding direct sales into Poland.
- LeMaitre Vascular ended 2025 with $359 million in cash and securities and announced a new $100 million share repurchase program and a 25% increase in its Q1 2026 dividend to $0.25 per share. The company is also actively pursuing M&A opportunities in open vascular and cardiac surgery, targeting companies with $15 million to $150 million in revenue.
3 days ago
LeMaitre Vascular Reports Q4 2025 Results, Increases Dividend, and Authorizes Share Repurchase
LMAT
Earnings
Guidance Update
Share Buyback
- LeMaitre Vascular reported Q4 2025 sales of $64.5 million, a 16% increase compared to Q4 2024, and diluted EPS of $0.68, up 39%.
- For the full year 2025, the company achieved 14% sales growth and 30% operating income growth.
- The company provided 2026 guidance, projecting sales of $280 million (midpoint, +12%) and diluted EPS of $2.91 (midpoint, +16% adjusted).
- The Board of Directors approved a 25% increase to the quarterly dividend, raising it to $0.25/share, and authorized a share repurchase program of up to $100.0 million.
3 days ago
LeMaitre Vascular Reports Strong Q3 2025 Financial Results and Updates Full-Year Guidance
LMAT
Earnings
Guidance Update
Product Launch
- LeMaitre Vascular reported Q3 2025 organic sales growth of 12% and an adjusted gross margin of 70.8%. Adjusted operating income increased 29% to $16.9 million, and adjusted diluted EPS rose 27% to $0.62.
- The company updated its full-year 2025 guidance, projecting $248 million in revenue (13% growth), an adjusted gross margin of 70.3%, and adjusted operating income of $63.7 million (22% increase). Full-year adjusted diluted EPS is expected to be $2.37, up 22%.
- Product highlights include grafts sales up 23% and shunts up 18% in Q3. The international Autograft launch continues to exceed expectations, with Q3 sales of $1.4 million and an anticipated $2 million in Q4. German approval for RestorFlow was received in October, with distribution expected in Q2 2026.
- LeMaitre Vascular ended Q3 with $343.1 million in cash and securities and generated $28.8 million in cash from operations. Management indicated that while the high cash balance provides optionality, they are not relaxing their standards for acquisitions.
- The company implemented an 8% price increase for its 2026 U.S. hospital price list, with 55% of North American revenue now subject to price floors. The sales force ended Q3 with 152 reps and aims for 165 reps by year-end.
Nov 6, 2025, 10:00 PM
LeMaitre Vascular Reports Q3 2025 Financial Results and Updates Guidance
LMAT
Earnings
Guidance Update
Dividends
- LeMaitre Vascular reported Q3 2025 sales of $61.0 million, an 11% increase (12% organic), with adjusted diluted EPS of $0.62, up 27%.
- The company's adjusted gross margin for Q3 2025 was 70.8% and adjusted operating income was $16.9 million. Cash increased by $23.6 million sequentially to $343.1 million at the end of Q3 2025.
- LeMaitre Vascular provided Q4 2025 sales guidance of $61.8 million to $63.8 million (midpoint $62.8 million) and full-year 2025 adjusted diluted EPS guidance of $2.37.
- A quarterly dividend of $0.20 per share was announced, and the company has an ongoing share repurchase program authorized for up to $75.0 million of common stock.
Nov 6, 2025, 9:03 PM
Quarterly earnings call transcripts for LEMAITRE VASCULAR.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more